EPIQ Partners’s Impel Pharmaceuticals Inc. Common Stock IMPL Stock Holding History

EPIQ Partners’s Portfolio IMPL Stock Details IMPL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-16,325	Closed	-$7.02K	–	74
2023 Q3	$7.02K	Sell	16,325 -2,321	-12%	-$2.23K	0.01%	67
2023 Q2	$23.7K	Hold	18,646	–	–	0.02%	77
2023 Q1	$26.1K	Hold	18,646	–	–	0.02%	76
2022 Q4	$69.9K	Hold	18,646	–	–	0.05%	74
2022 Q3	$91K	Hold	18,646	–	–	0.06%	79
2022 Q2	$174K	Hold	18,646	–	–	0.11%	81
2022 Q1	$119K	Hold	18,646	–	–	0.06%	90
2021 Q4	$161K	Buy	+18,646	New	+$186K	0.09%	87

Other funds holding IMPL

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

DJSG

D.J. St. Germain Springfield, Massachusetts $2.78B AUM 23.87% 1-Year Est. Return

EPIQ Partners's IMPL Position: Q4 2023 in Review

EPIQ Partners sold out of Impel Pharmaceuticals Inc. Common Stock (IMPL) in Q4 2023, closing a stake of 16,325 shares — an estimated $7.02K sold.

EPIQ Partners first reported a position in IMPL in Q4 2021 and held it in 8 quarters. The position peaked at $174K in Q2 2022. 2 funds tracked by Wall St. Rank hold IMPL as of Q4 2023.

EPIQ Partners reported no remaining Impel Pharmaceuticals Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
EPIQ Partners sold 16,325 Impel Pharmaceuticals Inc. Common Stock shares in Q4 2023, an estimated $7.02K.
EPIQ Partners first reported a position in Impel Pharmaceuticals Inc. Common Stock in Q4 2021 and held it in 8 quarters.
EPIQ Partners's Impel Pharmaceuticals Inc. Common Stock position peaked at $174K in Q2 2022.
2 funds tracked by Wall St. Rank held Impel Pharmaceuticals Inc. Common Stock as of Q4 2023.

Based on EPIQ Partners's 13F filing for Q4 2023, filed 11 Jan 2024.